Takeda in-licenses RCBs using SUREtechnology Platform

Takeda Pharmaceutical (TYO: 4502) it has entered a commercial license agreement (CLA) with Swiss biotech firm Selexis that provides with access to high-performance research cell banks (RCBs) developed using the Selexis SUREtechnology Platform.

Takeda, Japan’s largest drugmaker, is leveraging Selexis’ mammalian cell line-based protein expression platform to develop recombinant fusion proteins. No financial terms of the accord have been disclosed.

“Successfully developing a high-performance cell line expressing Takeda’s fusion proteins validates the strength of our SUREtechnology Platform,” said Yemi Onakunle, Selexis vice president, business development and licensing. “Through the systematic application of our platform under an initial licensing agreement, Selexis was able to isolate clones with very high productivity. We look forward to our continued work with Takeda under this agreement,” he added.